fibroblast growth factor receptor 2

Target id: 1809

Nomenclature: fibroblast growth factor receptor 2

Abbreviated Name: FGFR2

Family: Type V RTKs: FGF (fibroblast growth factor) receptor family

Annotation status:  image of an orange circle Annotated and awaiting review. Please contact us if you can help with reviewing.  » Email us

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 821 10q25.3-q26 FGFR2 fibroblast growth factor receptor 2
Mouse 1 840 7 Fgfr2 fibroblast growth factor receptor 2
Rat - 841 1q37 Fgfr2 fibroblast growth factor receptor 2
Previous and Unofficial Names
bacteria-expressed kinase
craniofacial dysostosis 1
Crouzon syndrome
Jackson-Weiss syndrome
keratinocyte growth factor receptor
Pfeiffer syndrome
Database Links
Ensembl Gene
Entrez Gene
GenitoUrinary Development Molecular Anatomy Project
Human Protein Reference Database
KEGG BRITE Hierarchy
Orphanet Gene
RefSeq Nucleotide
RefSeq Protein
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  Crystal Structure of Tyrosine Phosphorylated Activated FGF Receptor 2 (FGFR2) Kinase Domain in Complex with ATP Analog and Substrate Peptide
Resolution:  1.8Å
Species:  Human
References:  3
Enzyme Reaction
EC Number:
Endogenous ligands (Human)
FGF-1 (FGF1, P05230) > FGF-4 (FGF4, P08620), FGF-7 (FGF7, P21781), FGF-9 (FGF9, P31371) > FGF-2 (FGF2, P09038), FGF-6 (FGF6, P10767)  [8]
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
BGJ-398 Hs Inhibition 8.85 pIC50 6
pIC50 8.85 (IC50 1.4x10-9 M) [6]
AZD4547 Hs Inhibition >8.3 pIC50 2
pIC50 >8.3 (IC50 <5x10-9 M) [2]
nintedanib Hs Inhibition 7.43 pIC50 7
pIC50 7.43 (IC50 3.7x10-8 M) [7]
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Affinity Units Reference
palifermin Hs Agonist - -
DiscoveRx KINOMEscan® screen
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform.
Reference: 4,9

Key to terms and symbols Click column headers to sort
Target used in screen: FGFR2
Ligand Sp. Type Action Affinity Units
PD-173955 Hs Inhibitor Inhibition 7.51 pKd
cediranib Hs Inhibitor Inhibition 7.46 pKd
R406 Hs Inhibitor Inhibition 7.14 pKd
staurosporine Hs Inhibitor Inhibition 7.0 pKd
brivanib Hs Inhibitor Inhibition 6.96 pKd
axitinib Hs Inhibitor Inhibition 6.96 pKd
pazopanib Hs Inhibitor Inhibition 6.68 pKd
PP-242 Hs Inhibitor Inhibition 6.68 pKd
NVP-TAE684 Hs Inhibitor Inhibition 6.6 pKd
dovitinib Hs Inhibitor Inhibition 6.39 pKd
Displaying the top 10 most potent ligands  View all ligands in screen »
EMD Millipore KinaseProfilerTM screen/Reaction Biology Kinase HotspotSM screen
A screen profiling 158 kinase inhibitors (Calbiochem Protein Kinase Inhibitor Library I and II, catalogue numbers 539744 and 539745) for their inhibitory activity at 1µM and 10µM against 234 human recombinant kinases using the EMD Millipore KinaseProfilerTM service.

A screen profiling the inhibitory activity of 178 commercially available kinase inhibitors at 0.5µM against a panel of 300 recombinant protein kinases using the Reaction Biology Corporation Kinase HotspotSM platform.

Reference: 1,5

Key to terms and symbols Click column headers to sort
Target used in screen: FGFR2/FGFR2
Ligand Sp. Type Action % Activity remaining at 0.5µM % Activity remaining at 1µM % Activity remaining at 10µM
staurosporine Hs Inhibitor Inhibition 3.2 1.0 0.0
Cdk1/2 inhibitor III Hs Inhibitor Inhibition 7.4 1.0 -1.0
dovitinib Hs Inhibitor Inhibition 22.0
SU11652 Hs Inhibitor Inhibition 29.3 14.0 3.0
SB 218078 Hs Inhibitor Inhibition 34.1 83.0 78.0
PKR inhibitor Hs Inhibitor Inhibition 37.6 18.0 3.0
vandetanib Hs Inhibitor Inhibition 38.4
pazopanib Hs Inhibitor Inhibition 40.2
K-252a Hs Inhibitor Inhibition 45.4 20.0 2.0
GSK-3beta inhibitor XII Hs Inhibitor Inhibition 46.1 21.0 2.0
Displaying the top 10 most potent ligands  View all ligands in screen »
Clinically-Relevant Mutations and Pathophysiology
Disease:  Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis
OMIM:  207410
Orphanet:  83
Disease:  Apert syndrome
OMIM:  101200
Orphanet:  87
Disease:  Beare-Stevenson cutis gyrata syndrome
OMIM:  123790
Orphanet:  1555
Disease:  Bent bone dysplasia syndrome
OMIM:  614592
Orphanet:  313855
Disease:  Crouzon disease
OMIM:  123500
Orphanet:  207
Disease:  Jackson-Weiss syndrome
OMIM:  123150
Orphanet:  1540
Disease:  Lacrimoauriculodentodigital syndrome
OMIM:  149730
Orphanet:  2363
Disease:  Pfeiffer syndrome type 1
OMIM:  101600
Orphanet:  93258
Disease:  Pfeiffer syndrome type 2
OMIM:  101600
Orphanet:  93259
Disease:  Pfeiffer syndrome type 3
OMIM:  101600
Orphanet:  93260
Disease:  Saethre-Chotzen syndrome
OMIM:  101400
Orphanet:  794
Disease:  Scaphocephaly, maxillary retrusion, and mental retardation
OMIM:  609579
Orphanet:  168624


Show »

1. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol.29 (11): 1039-45. [PMID:22037377]

2. AstraZeneca. AZD4547. Accessed on 11/09/2014. Modified on 11/09/2014.,

3. Chen H, Ma J, Li W, Eliseenkova AV, Xu C, Neubert TA, Miller WT, Mohammadi M. (2007) A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol. Cell27 (5): 717-30. [PMID:17803937]

4. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol.29 (11): 1046-51. [PMID:22037378]

5. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ. (2013) A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem. J.451 (2): 313-28. [PMID:23398362]

6. Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C, Brueggen J, Jensen MR, Schnell C, Schmid H et al.. (2011) Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J. Med. Chem.54 (20): 7066-83. [PMID:21936542]

7. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J et al.. (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res.68 (12): 4774-82. [PMID:18559524]

8. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M. (1996) Receptor specificity of the fibroblast growth factor family. J. Biol. Chem.271 (25): 15292-7. [PMID:8663044]

9. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem. Biol.17 (11): 1241-9. [PMID:21095574]

How to cite this page

Type V RTKs: FGF (fibroblast growth factor) receptor family: fibroblast growth factor receptor 2. Last modified on 04/11/2014. Accessed on 01/03/2015. IUPHAR/BPS Guide to PHARMACOLOGY,